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Orphan metabolic diseases are rare genetic defects that interfere with metabolism due to ineffective or missing 
enzymes. Two of them, Phenylketonuria (PKU) and Maple Syrup Urine Disease (MSUD) are defined by 
accumulation of amino acids to toxic levels due to defective metabolism of protein break down products. PKU is 
caused by a defect in the gene encoding phenylalanine hydroxylase (PAH). MSUD is caused by a defect in a 
multi-enzyme complex found in mitochondria called branched chain ɑ-ketoacid dehydrogenase “BCKDH”. 
Without the activity of these enzymes, the amino acid phenylalanine (Phe) in the case of PKU or the branched-
chain amino acids leucine (Leu), isoleucine and valine for MSUD build up to neurotoxic levels in the blood and 
brain, leading to neurological deficits. Current treatment options focus on dietary protein restriction, are 
insufficient and, unfortunately, can lead to a failure to thrive. Lifelong compliance with a prescription diet is also 
a concern. We have genetically engineered Nissle, a probiotic strain of E. coli, to reduce serum phenylalanine 
and leucine levels in patients with PKU or MSUD; preclinical data supporting the activity of these strains are 
described. 
 
 
